Filing Flows › Gilead Sciences (GILD) › Guidance & outlook
Gilead Sciences (GILD) guidance and outlook
Gilead Sciences (GILD) raised some and lowered other parts of its guidance on Oct 29, 2026: EPS −$4.40 for FY2026; EPS $9.88 for FY2026; EPS $9.88 for FY2026; Gross margin 79% for FY2026. Gilead Sciences' 10-Q filed Oct 30, 2026 makes 4 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.6B | raised |
| EPS | FY2026 | −$4.40 | lowered |
| EPS | FY2026 | $9.88 | raised |
| EPS | FY2026 | $9.88 | raised |
| Gross margin | FY2026 | 79% | reaffirmed |
| Gross margin | FY2026 | 87% | reaffirmed |
| Tax rate | FY2026 | 21% | reaffirmed |
| Tax rate | FY2026 | 20% | reaffirmed |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 30, 2026
- The new price will be effective and impact our Biktarvy revenue starting January 1, 2028.
- We manage these expenses by identifying the research and development (“R&D”) activities we expect to be performed during a given period and then prioritizing efforts based on scientific data, probability of successful technical development and regulatory approval, market potential, available human and capital resources and other considerations.
- We regularly review our R&D activities based on unmet medical need and, as necessary, reallocate resources among our internal R&D portfolio and external opportunities that we believe will best support the long-term growth of our business.
- In consideration of this decision, and in connection with the preparation of the financial statements for the second quarter of 2026, we determined that no future cash flows were expected to be generated in relation to the NSCLC IPR&D intangible asset, and therefore, no value was attributed to the asset.
Gilead Sciences' latest quarter
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Questions
Did Gilead Sciences raise or lower its guidance?
Gilead Sciences (GILD) raised some and lowered other parts of its guidance on Oct 29, 2026: EPS −$4.40 for FY2026; EPS $9.88 for FY2026; EPS $9.88 for FY2026; Gross margin 79% for FY2026.
What does Gilead Sciences expect?
The new price will be effective and impact our Biktarvy revenue starting January 1, 2028. We manage these expenses by identifying the research and development (“R&D”) activities we expect to be performed during a given period and then prioritizing efforts based on scientific data, probability of successful technical development and regulatory approval, market potential, available human and capital resources and other considerations. We regularly review our R&D activities based on unmet medical need and, as necessary, reallocate resources among our internal R&D portfolio and external opportunit
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.